ClinicalTrials.gg
CompletedNCT00043381Updated Aug 2, 2024

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

A Phase 3 interventional study of decitabine (5-aza-2'deoxycytidine) in Myelodysplastic Syndrome, sponsored by Astex Pharmaceuticals, Inc.. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Enrollment
9th of 74
160 · median 43
Started
2001
the only one that year
Phase 3
3 of 75
none open now
Registered
5th of 75
by date
Lead sponsor
2 of 75
Astex Pharmaceuticals, Inc.

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 9th largest by enrollment of the 74 interventional ones that give a count, is the only one that started in 2001, is one of 3 in phase 3, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

To compare the safety and efficacy profiles of decitabine to those of supportive care in adults with advanced-stage myelodysplastic syndrome (MDS)

Read the detailed description

This experimental (investigational) study is intended to answer the question of whether decitabine is any better than supportive care alone in delaying progression (worsening) of the disease, prolonging survival or improving the overall quality of life for MDS patients who are not candidates for bone marrow transplant (BMT).

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • myelodysplastic syndrome
  • MDS
  • chronic myelomonocytic leukemia
  • CMML
  • decitabine
  • 5-aza-2'deoxycytidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MDS (de novo or secondary) fitting any of the recognized French-American-British, FAB, classifications or chronic myelomonocytic leukemia (CMML) with WBC \< 12,000/mm3, AND International Prognostic Scoring System (IPSS) >/= 0.5 as determined by CBC, bone marrow assessment and bone marrow cytogenetics within 30 days of randomization
  • 18 years or older
  • Female patients of must have a negative serum hCG within 24 hours prior to randomization, must practice a medically approved method of for the past 30 days, and agree to continue this practice for the trial duration and must not be breast-feeding
  • or WHO performance status of 0-2
  • Written
  • Normal renal and hepatic function (creatinine \</= 2 mg/dL, \</= 1.5 mg/dL, \</= 2 times the )

Exclusion criteria

Exclusion:

  • Acute Myeloid Leukemia (AML) (>/=30% bone marrow blasts) or other progressive malignant disease
  • Patients must have recovered from the toxic effects of prior therapy and must be off all chemotherapy for a minimum of 4 weeks prior to study entry to the protocol (a minimum of six weeks for prior nitrosoureas and bone marrow transplantation)
  • Ongoing treatment with androgenic hormones, danazol, colony-stimulating factors, or other agents used to treat MDS within 7 days of study initiation.
  • Administration of any agent within the 30 days preceding study initiation.
  • Uncontrolled cardiac disease or congestive heart failure
  • Uncontrolled restrictive or obstructive pulmonary disease
  • Active viral or bacterial infection
  • Superimposed hemolytic anemia or thrombocytopenia
  • Known positive serology for
  • Mental illness or other condition preventing full cooperation with the treatment and monitoring requirements of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants
06

Study locations

24 sites
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California, United States
  • City of Hope National Medical Center
    Duarte, California, United States
  • Scripps Clinic
    Escondido, California, United States
  • Loma Linda Univ. Cancer Center
    Loma Linda, California, United States
  • Univ. California San Francisco Medical School
    San Francisco, California, United States
  • University of Florida
    Gainesville, Florida, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida, United States
  • James A. Haley Veteran's Hospital
    Tampa, Florida, United States
  • Rush Medical Center
    Chicago, Illinois, United States
  • University of Illinois at Chicago
    Chicago, Illinois, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
  • New England Medical Center Hospital
    Boston, Massachusetts, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts, United States
  • VA Medical Center
    Minneapolis, Minnesota, United States
  • Washington Univ. School of Medicine
    Saint Louis, Missouri, United States
  • Roswell Park Cancer Institute
    Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Mount Sinai Medical Center
    New York, New York, United States
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina, United States
  • Duke University Medical Center
    Durham, North Carolina, United States
  • The Memphis Cancer Center
    Memphis, Tennessee, United States
  • SW Regional Cancer Center (dba Central Texas Oncology Associates)
    Austin, Texas, United States
  • Texas Oncology
    Dallas, Texas, United States
  • MD Anderson Cancer Center
    Houston, Texas, United States
07

References and documents

Publications

  • Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):592-6. doi: 10.1016/j.clml.2013.05.004. Epub 2013 Jun 20. PubMed 23790798 ↗
  • Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):131-8. doi: 10.1016/j.clml.2012.11.001. Epub 2012 Dec 21. PubMed 23260600 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of Nov 2002 and a completion of Apr 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2002
First posted
Aug 12, 2002
Start
Apr 2001
Primary completionActual
Nov 2002
CompletionActual
Apr 2003
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00043381
First posted
Aug 12, 2002
Start date
Apr 2001
Primary completion
Nov 2002
Completion
Apr 2003
Last update
Aug 2, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion